Pathologic Findings at Risk Reducing Surgery in BRCA and Non- BRCA Mutation Carriers: A Single-Center Experience.

Cassani, Chiara; Rossi, Chiara; Camnasio, Cristina Angela; Urtis, Mario; Fiandrino, Giacomo; Grasso, Maurizia; Zanellini, Francesca; Lucioni, Marco; D'Ambrosio, Gioacchino; Di Toro, Alessandro; Rossi, Margherita; Roccio, Marianna; Ferrari, Alberta; Secondino, Simona; Nappi, Rossella Elena; Arbustini, Eloisa; Paulli, Marco; Spinillo, Arsenio; Cesari, Stefania

Risk-reducing surgery (RRS) is recommended in BRCA-mutated carriers because of their increased risk of developing ovarian cancer, while its role is still discussed for women harboring mutations in non-BRCA homologous repair genes. The aim of this study was to retrospectively evaluate the occurrence of pathological findings in a high-risk population undergoing RRS in San Matteo Hospital, Pavia between 2012 and 2022, and correlate their genetic and clinical outcomes, comparing them with a control group. The final cohort of 190 patients included 85 BRCA1, 63 BRCA2, 11 CHEK2, 7 PALB2, 4 ATM, 1 ERCC5, 1 RAD51C, 1 CDH1, 1 MEN1, 1 MLH1 gene mutation carriers and 15 patients with no known mutation but with strong familial risk. Occult invasive serous carcinoma (HGSC) and serous tubal intraepithelial carcinoma (STIC) were diagnosed in 12 (6.3%) women, all of them BRCA carriers. No neoplastic lesion was diagnosed in the non-BRCA group, in women with familial risk, or in the control group. Oral contraceptive use and age ≤45 at surgery were both found to be favorable factors. While p53 signature and serous tubal intraepithelial lesion (STIL) were also seen in the control group and in non-BRCA carriers, STIC and HGSC were only found in BRCA1/2 mutation carriers.

BRCA genes; OVARIAN cancer; GENETIC mutation; CONTRACEPTION; ORAL contraceptives; CHECKPOINT kinase 2

Diagnostics (2075-4418), 2022, Vol 12, Issue 12, p3054

2075-4418

Academic Journal

10.3390/diagnostics12123054